泽璟制药：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准

Core Viewpoint - ZG006, a trispecific antibody developed by the company, has received approval for clinical trials in combination with PD-1/PD-L1 inhibitors and chemotherapy for small cell lung cancer from the National Medical Products Administration (NMPA) of China [1][2] Group 1 - ZG006 (INN name: alveltamig) is the first trispecific antibody targeting DLL3, developed through the company's dual/multi-specific antibody platform [1] - The drug has received clinical trial approvals from both the U.S. FDA and China's NMPA, and has been designated as a breakthrough therapy and orphan drug [1] - ZG006 targets two different DLL3 epitopes and CD3, effectively bridging T cells and tumor cells to enhance T cell-mediated tumor cell killing [2] Group 2 - Preclinical studies have shown that ZG006 exhibits significant tumor suppression in mouse models, leading to a notable proportion of complete tumor regression [2] - The drug demonstrates strong tumor-killing efficacy, indicating its potential as a best-in-class molecule in its category [1][2]